DK1895010T3 - Vektorer baseret på virus for infektiøs hesteanæmi (eiav) - Google Patents
Vektorer baseret på virus for infektiøs hesteanæmi (eiav)Info
- Publication number
- DK1895010T3 DK1895010T3 DK07015653.4T DK07015653T DK1895010T3 DK 1895010 T3 DK1895010 T3 DK 1895010T3 DK 07015653 T DK07015653 T DK 07015653T DK 1895010 T3 DK1895010 T3 DK 1895010T3
- Authority
- DK
- Denmark
- Prior art keywords
- eiav
- infectious
- viruses
- vectors based
- anemia
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15051—Methods of production or purification of viral material
- C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15061—Methods of inactivation or attenuation
- C12N2740/15062—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
- C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9727135.7A GB9727135D0 (en) | 1997-12-22 | 1997-12-22 | Non-primate lentiviral vectors |
| GBGB9811037.2A GB9811037D0 (en) | 1998-05-22 | 1998-05-22 | Proretoviral vectors |
| EP98962602A EP1042493A1 (en) | 1997-12-22 | 1998-12-22 | Equine infectious anaemia virus (eiav) based retroviral vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1895010T3 true DK1895010T3 (da) | 2011-11-21 |
Family
ID=26312829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07015653.4T DK1895010T3 (da) | 1997-12-22 | 1998-12-22 | Vektorer baseret på virus for infektiøs hesteanæmi (eiav) |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US6312683B1 (da) |
| EP (2) | EP1895010B1 (da) |
| JP (1) | JP4578678B2 (da) |
| CN (1) | CN1322137C (da) |
| AT (1) | ATE528405T1 (da) |
| AU (1) | AU760287B2 (da) |
| CA (1) | CA2315269A1 (da) |
| CY (1) | CY1112196T1 (da) |
| DK (1) | DK1895010T3 (da) |
| ES (1) | ES2373406T3 (da) |
| PT (1) | PT1895010E (da) |
| WO (1) | WO1999032646A1 (da) |
Families Citing this family (114)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040266715A1 (en) * | 1999-03-31 | 2004-12-30 | Wong Liang Fong | Neurite regeneration |
| US20070213290A1 (en) * | 1996-10-17 | 2007-09-13 | Kingsman Alan J | Neurite regeneration |
| EP1895010B1 (en) * | 1997-12-22 | 2011-10-12 | Oxford Biomedica (UK) Limited | Equine infectious anaemia virus (eiav) based vectors |
| GB9803351D0 (en) | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
| US6849454B2 (en) | 2000-03-07 | 2005-02-01 | St. Jude Children's Research Hospital | Highly efficient gene transfer into human repopulating stem cells by RD114 pseudotyped retroviral vector particles |
| AU2001240078A1 (en) * | 2000-03-07 | 2001-09-17 | St. Jude Children's Research Hospital | Highly efficient gene transfer into human repopulating stem cells by rd114 pseudotyped retroviral vector particles |
| CA2399399A1 (en) * | 2000-03-30 | 2001-10-11 | Oxford Biomedica (Uk) Limited | Retinoic acid receptor beta-2, its antagonists, and gene therapy vectors for the treatment of neurological disorders |
| GB0009760D0 (en) * | 2000-04-19 | 2000-06-07 | Oxford Biomedica Ltd | Method |
| US20040018211A1 (en) * | 2002-06-26 | 2004-01-29 | Ronald Montelaro | EIA vaccine and diagnostic |
| BR0113745A (pt) * | 2000-09-09 | 2004-03-02 | Akzo Nobel Nv | Vacina, teste diagnóstico e métodos para imunizar mamìferos e para preparar uma vacina |
| US6585978B1 (en) * | 2000-09-09 | 2003-07-01 | Akzo Nobel | EIA vaccine and diagnostic |
| US6461616B1 (en) * | 2000-09-09 | 2002-10-08 | Akzo Nobel Nv | EIAV p26 deletion vaccine and diagnostic |
| AU9184901A (en) * | 2000-09-14 | 2002-03-26 | Ares Trading Sa | Use of il-6r/il-6 chimera in huntington's disease |
| GB0024550D0 (da) | 2000-10-06 | 2000-11-22 | Oxford Biomedica Ltd | |
| WO2002034929A2 (en) * | 2000-10-20 | 2002-05-02 | Whitehead Institute For Biomedical Research | Expression vectors and uses thereof |
| US7575924B2 (en) | 2000-11-13 | 2009-08-18 | Research Development Foundation | Methods and compositions relating to improved lentiviral vectors and their applications |
| US6712612B1 (en) | 2000-12-12 | 2004-03-30 | Genecure Llc | Safe and stable retroviral helper cell line and related compositions and methods |
| CA2344208A1 (en) | 2001-04-30 | 2002-10-30 | Oxford Biomedica (Uk) Limited | Method |
| WO2003012054A2 (en) | 2001-08-02 | 2003-02-13 | Institut Clayton De La Recherche | Methods and compositions relating to improved lentiviral vector production systems |
| EP1438399A4 (en) * | 2001-09-28 | 2005-09-14 | Univ North Carolina | PARAMYXOVIRUSES AS GENE TRANSFER VECTORS TO PULMONARY CELLS |
| JP2005504539A (ja) * | 2001-10-02 | 2005-02-17 | インスティテュット クレイトン ド ラ リシェルシュ | 制限発現レンチウイルス性ベクターに関連する方法及び組成物並びにその応用 |
| US20030121062A1 (en) * | 2001-12-21 | 2003-06-26 | Oxford Biomedica (Uk) Limited | Transgenic organism |
| CN1620508A (zh) * | 2001-12-21 | 2005-05-25 | 牛津生物医学（英国）有限公司 | 转基因生物 |
| US9738907B2 (en) | 2002-02-01 | 2017-08-22 | Oxford Biomedica (Uk) Limited | Viral vector |
| ES2634424T3 (es) | 2002-02-01 | 2017-09-27 | Oxford Biomedica (Uk) Limited | Vector multicistrónico lentivírico |
| GB0215287D0 (en) * | 2002-07-02 | 2002-08-14 | Oxford Biomedica Ltd | 5T4 antigen expression |
| US7662625B2 (en) * | 2002-07-02 | 2010-02-16 | Cancer Research Technology Limited | Methods for detecting the differentiation status of cells using 5T4 antigen expression |
| GB0220467D0 (en) | 2002-09-03 | 2002-10-09 | Oxford Biomedica Ltd | Composition |
| WO2004022761A1 (en) * | 2002-09-03 | 2004-03-18 | Oxford Biomedica (Uk) Limited | Retroviral vector and stable packaging cell lines |
| US20050251872A1 (en) * | 2002-09-06 | 2005-11-10 | Bear James E | Lentiviral vectors, related reagents, and methods of use thereof |
| US20050014166A1 (en) * | 2002-11-22 | 2005-01-20 | Institut Clayton De La Recherche | Compositions and systems for the regulation of genes |
| EP2390352A1 (en) | 2003-03-18 | 2011-11-30 | Quantum Genetics Ireland Limited | Systems and methods for improving protein and milk production of dairy herds |
| US7468273B2 (en) | 2003-05-01 | 2008-12-23 | Meial Limited | Canine GHRH gene, polypeptides and methods of use |
| AU2004289953B2 (en) | 2003-06-18 | 2008-09-25 | Genelux Corporation | Modified recombinant vaccina viruses and other microorganisms, uses thereof |
| EP1689858B1 (en) | 2003-11-13 | 2013-05-15 | University Of Georgia Research Foundation, Inc. | Methods of characterizing infectious bursal disease virus |
| CA2556911C (en) | 2004-02-19 | 2013-07-30 | The Governors Of The University Of Alberta | Leptin promoter polymorphisms and uses thereof |
| FR2870126B1 (fr) | 2004-05-17 | 2009-07-17 | Pasteur Institut | Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin |
| US20060233757A1 (en) * | 2004-08-27 | 2006-10-19 | Wendy Maury | Vectors with viral insulators |
| CA2605629C (en) | 2005-04-25 | 2012-06-26 | Merial Limited | Nipah virus vaccines |
| US20080241184A1 (en) | 2005-08-25 | 2008-10-02 | Jules Maarten Minke | Canine influenza vaccines |
| US7771995B2 (en) | 2005-11-14 | 2010-08-10 | Merial Limited | Plasmid encoding human BMP-7 |
| EP3536704B1 (en) | 2005-11-14 | 2021-08-25 | Boehringer Ingelheim Animal Health USA Inc. | Gene therapy for renal failure |
| US7862821B2 (en) | 2006-06-01 | 2011-01-04 | Merial Limited | Recombinant vaccine against bluetongue virus |
| EP2415783B1 (en) | 2006-10-16 | 2016-12-14 | Genelux Corporation | Modified vaccinia virus strains for use in a diagnostic and therapeutic method |
| GB0702695D0 (en) * | 2007-02-12 | 2007-03-21 | Ark Therapeutics Ltd | Production of vectors |
| CN101705246B (zh) * | 2007-04-29 | 2012-06-27 | 中国农业科学院哈尔滨兽医研究所 | 慢病毒基因转移载体、其制备方法和应用 |
| EP2209889B1 (en) | 2007-11-16 | 2016-07-20 | San Diego State University Research Foundation | Compositions for manipulating pim-1 activity in cardiac cells |
| US8871220B2 (en) | 2009-04-03 | 2014-10-28 | Merial Limited | Newcastle disease virus vectored avian vaccines |
| US8986706B2 (en) | 2010-08-31 | 2015-03-24 | Merial, Inc. | Newcastle disease virus vectored herpesvirus vaccines |
| WO2012090073A2 (en) | 2010-12-30 | 2012-07-05 | The Netherlands Cancer Institute | Methods and compositions for predicting chemotherapy sensitivity |
| WO2012138789A2 (en) | 2011-04-04 | 2012-10-11 | Netherlands Cancer Institute | Methods and compositions for predicting resistance to anticancer treatment |
| AU2012240240A1 (en) | 2011-04-04 | 2013-05-09 | Netherlands Cancer Institute | Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors |
| WO2012145577A1 (en) | 2011-04-20 | 2012-10-26 | Merial Limited | Adjuvanted rabies vaccine with improved viscosity profile |
| AP2013007180A0 (en) | 2011-04-25 | 2013-10-31 | Advanced Bioscience Lab Inc | Truncated HIV envelope proteins (ENV), methods andcompositions related thereto |
| WO2012166493A1 (en) | 2011-06-01 | 2012-12-06 | Merial Limited | Needle-free administration of prrsv vaccines |
| WO2013093629A2 (en) | 2011-12-20 | 2013-06-27 | Netherlands Cancer Institute | Modular vaccines, methods and compositions related thereto |
| GB201202516D0 (en) | 2012-02-13 | 2012-03-28 | Ucl Business Plc | Materials and methods relating to packaging cell lines |
| WO2013138776A1 (en) | 2012-03-16 | 2013-09-19 | Merial Limited | Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g |
| US10106816B2 (en) * | 2012-12-14 | 2018-10-23 | Case Western Reserve University | Genomic RNA packaging enhancer element |
| US9556419B2 (en) | 2013-03-12 | 2017-01-31 | Merial Inc. | Reverse genetics Schmallenberg virus vaccine compositions, and methods of use thereof |
| GB201318804D0 (en) | 2013-10-24 | 2013-12-11 | Adaptimmune Ltd | Vectors for transgene expression |
| GB201322798D0 (en) | 2013-12-20 | 2014-02-05 | Oxford Biomedica Ltd | Production system |
| US10010499B2 (en) | 2014-11-03 | 2018-07-03 | Merial Inc. | Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus |
| PL3313864T3 (pl) | 2015-06-23 | 2022-01-03 | Boehringer Ingelheim Animal Health USA Inc. | Rekombinowane wektory wirusowe zawierające drugorzędne białko prrsv oraz sposoby ich wytwarzania i zastosowania |
| EP3380620B1 (en) | 2015-11-23 | 2024-07-03 | Novartis AG | Optimized lentiviral transfer vectors and uses thereof |
| JP7277388B2 (ja) | 2017-03-15 | 2023-05-18 | オックスフォード バイオメディカ（ユーケー）リミテッド | 方法 |
| ES2951857T3 (es) | 2017-12-22 | 2023-10-25 | Oxford Biomedica Ltd | Vector retroviral |
| IL278665B1 (en) | 2018-05-15 | 2024-06-01 | Flagship Pioneering Innovations V Inc | Pozosome preparations and their uses |
| BR112021000145A2 (pt) | 2018-07-09 | 2021-04-06 | Flagship Pioneering Innovations V, Inc | Composições de fusossoma e usos das mesmas |
| EP3880832A1 (en) | 2018-11-14 | 2021-09-22 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for hematopoietic stem cell delivery |
| WO2020102503A2 (en) | 2018-11-14 | 2020-05-22 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for t cell delivery |
| US20220008557A1 (en) | 2018-11-14 | 2022-01-13 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for cns delivery |
| US20220333132A1 (en) | 2019-09-03 | 2022-10-20 | Sana Blotechnology, Inc. | Cd24-associated particles and related methods and uses thereof |
| JP2023504593A (ja) | 2019-11-12 | 2023-02-06 | オックスフォード バイオメディカ（ユーケー）リミテッド | 産生系 |
| CA3164986A1 (en) | 2019-12-20 | 2021-06-24 | Instil Bio (Uk) Limited | Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof |
| US20240052366A1 (en) | 2020-02-13 | 2024-02-15 | Oxford Biomedica (Uk) Limited | Production of Lentiviral Vectors |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| CN115667534A (zh) | 2020-03-13 | 2023-01-31 | 牛津生物医学（英国）有限公司 | 慢病毒载体 |
| IL296621A (en) | 2020-03-31 | 2022-11-01 | Sana Biotechnology Inc | Targeted lipid particles and their preparations and uses |
| CA3177006A1 (en) | 2020-04-27 | 2022-10-26 | University Of Iowa Research Foundation | Compositions and methods for the treatment of cystic fibrosis |
| GB202007199D0 (en) | 2020-05-15 | 2020-07-01 | Oxford Biomedica Ltd | Viral vector production |
| US20230190871A1 (en) | 2020-05-20 | 2023-06-22 | Sana Biotechnology, Inc. | Methods and compositions for treatment of viral infections |
| JP2023540705A (ja) | 2020-08-28 | 2023-09-26 | サナ バイオテクノロジー，インコーポレイテッド | 修飾された抗ウイルス結合剤 |
| GB202017725D0 (en) | 2020-11-10 | 2020-12-23 | Oxford Biomedica Ltd | Method |
| CA3205462A1 (en) | 2020-12-18 | 2022-06-23 | Instil Bio (Uk) Limited | Processing of tumor infiltrating lymphocytes |
| JP2023554425A (ja) | 2020-12-18 | 2023-12-27 | インスティル バイオ （ユーケイ） リミテッド | 腫瘍浸潤リンパ球の処理 |
| WO2022130016A1 (en) | 2020-12-18 | 2022-06-23 | Instil Bio (Uk) Limited | Tumor infiltrating lymphocytes and anti-cd47 therapeutics |
| AU2022206324A1 (en) | 2021-01-11 | 2023-07-20 | Sana Biotechnology, Inc. | Use of cd8-targeted viral vectors |
| CN117980495A (zh) * | 2021-03-24 | 2024-05-03 | 国家抗灾力公司 | 用于无细胞多肽合成的***和方法 |
| CN117642420A (zh) | 2021-05-28 | 2024-03-01 | 萨那生物科技公司 | 含有截短的狒狒内源性逆转录病毒(BaEV)包膜糖蛋白的脂质颗粒及相关方法和用途 |
| EP4381081A1 (en) | 2021-08-04 | 2024-06-12 | Sana Biotechnology, Inc. | Use of cd4-targeted viral vectors |
| TW202321456A (zh) * | 2021-09-08 | 2023-06-01 | 日商寶生物股份有限公司 | 反轉錄病毒載體製造用之核酸 |
| GB202114532D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Lentiviral Vectors |
| GB202114534D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Novel viral regulatory elements |
| GB202114530D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Retroviral vectors |
| GB202114529D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Lentiviral vectors |
| GB202114528D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Lentiviral vectors |
| WO2023077107A1 (en) | 2021-10-29 | 2023-05-04 | Sana Biotechnology, Inc. | Methods and reagents for amplifying viral vector nucleic acid products |
| GB202117844D0 (en) | 2021-12-09 | 2022-01-26 | Oxford Biomedica Ltd | Purification method |
| WO2023114949A1 (en) | 2021-12-16 | 2023-06-22 | Sana Biotechnology, Inc. | Methods and systems of particle production |
| TW202342498A (zh) | 2021-12-17 | 2023-11-01 | 美商薩那生物科技公司 | 經修飾副黏液病毒科融合醣蛋白 |
| WO2023115041A1 (en) | 2021-12-17 | 2023-06-22 | Sana Biotechnology, Inc. | Modified paramyxoviridae attachment glycoproteins |
| WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023150518A1 (en) | 2022-02-01 | 2023-08-10 | Sana Biotechnology, Inc. | Cd3-targeted lentiviral vectors and uses thereof |
| WO2023150647A1 (en) | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| GB202211935D0 (en) | 2022-08-16 | 2022-09-28 | Oxford Biomedica Ltd | envelope proteins |
| WO2024044655A1 (en) | 2022-08-24 | 2024-02-29 | Sana Biotechnology, Inc. | Delivery of heterologous proteins |
| WO2024064838A1 (en) | 2022-09-21 | 2024-03-28 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
| WO2024081820A1 (en) | 2022-10-13 | 2024-04-18 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
| WO2024103025A1 (en) * | 2022-11-11 | 2024-05-16 | Rnaissance Ag Llc | Fermentation based method for double stranded rna production |
| WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5747324A (en) * | 1988-06-10 | 1998-05-05 | Therion Biologics Corporation | Self-assembled, defective, non-self-propagating lentivirus particles |
| US5631154A (en) * | 1988-06-10 | 1997-05-20 | Therion Biologics, Incorporated | Self assembled, defective, non-self-propagating lentivirus particles |
| JP3247972B2 (ja) * | 1990-05-28 | 2002-01-21 | 財団法人阪大微生物病研究会 | レトロウイルス遺伝子の多量発現能と翻訳後のプロセッシング能とを兼備するプラスミドの作製法、及びこれより得られるプラスミドとその発現産物 |
| JP3264281B2 (ja) | 1990-06-20 | 2002-03-11 | デイナ・フアーバー・キヤンサー・インステイテユート | Ｈｉｖパッケージング配列を含むベクター、パッケージング不全ｈｉｖベクター及びその使用 |
| US5981276A (en) * | 1990-06-20 | 1999-11-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
| CA2109579A1 (en) | 1991-05-29 | 1992-12-10 | Julianna Lisziewicz | Eukaryotic expression vectors with regulation of rna processing |
| EP0611822B1 (en) | 1993-02-17 | 2002-05-22 | Wisconsin Alumni Research Foundation | More complex type retroviruses having mixed type LTR, and uses thereof |
| WO1995030763A2 (en) * | 1994-05-09 | 1995-11-16 | Chiron Viagene, Inc. | Retroviral vectors having a reduced recombination rate |
| WO1995030755A1 (fr) | 1994-05-10 | 1995-11-16 | Hisamitsu Pharmaceutical Co., Inc. | Vecteur recombinant du virus de l'immunodeficience humaine et procede pour sa production |
| AU688590B2 (en) * | 1994-09-02 | 1998-03-12 | Gsf - Forschungszentrum Fur Umwelt Und Gesundheit Gmbh | Non self-inactivating, expression targeted retroviral vectors |
| US6300118B1 (en) * | 1995-06-07 | 2001-10-09 | American Home Products Corporation | Plasmids comprising a genetically altered feline immunodeficiency virus genome |
| US6013516A (en) * | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US6033672A (en) * | 1996-03-15 | 2000-03-07 | University Of Southern California | Method of stimulating an immune response to caprine arthritis-encephalitis virus (CAEV) in humans through the administration of CAEV immunogens |
| GB2325003B (en) * | 1996-10-17 | 2000-05-10 | Oxford Biomedica Ltd | Rectroviral vectors |
| JP2001513643A (ja) * | 1997-03-06 | 2001-09-04 | ウーベルラ、クラウス | レンチウイルスをベースとするベクター及びベクター系 |
| US6207455B1 (en) * | 1997-05-01 | 2001-03-27 | Lung-Ji Chang | Lentiviral vectors |
| CN1247788C (zh) * | 1997-05-13 | 2006-03-29 | 北卡罗来纳-查佩尔山大学 | 基于慢病毒的基因转移载体 |
| GB9720465D0 (en) * | 1997-09-25 | 1997-11-26 | Oxford Biomedica Ltd | Dual-virus vectors |
| ES2245042T3 (es) * | 1997-09-24 | 2005-12-16 | The Regents Of The University Of California | Vectores de lentivirus de no primates y sistemas de empaquetamiento. |
| US5994136A (en) * | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| EP1895010B1 (en) * | 1997-12-22 | 2011-10-12 | Oxford Biomedica (UK) Limited | Equine infectious anaemia virus (eiav) based vectors |
-
1998
- 1998-12-22 EP EP07015653A patent/EP1895010B1/en not_active Expired - Lifetime
- 1998-12-22 CA CA002315269A patent/CA2315269A1/en not_active Abandoned
- 1998-12-22 CN CNB988137666A patent/CN1322137C/zh not_active Expired - Lifetime
- 1998-12-22 JP JP2000525564A patent/JP4578678B2/ja not_active Expired - Lifetime
- 1998-12-22 DK DK07015653.4T patent/DK1895010T3/da active
- 1998-12-22 ES ES07015653T patent/ES2373406T3/es not_active Expired - Lifetime
- 1998-12-22 AT AT07015653T patent/ATE528405T1/de active
- 1998-12-22 AU AU17732/99A patent/AU760287B2/en not_active Expired
- 1998-12-22 WO PCT/GB1998/003876 patent/WO1999032646A1/en not_active Application Discontinuation
- 1998-12-22 PT PT07015653T patent/PT1895010E/pt unknown
- 1998-12-22 EP EP98962602A patent/EP1042493A1/en not_active Withdrawn
-
1999
- 1999-01-27 US US09/238,356 patent/US6312683B1/en not_active Expired - Lifetime
-
2001
- 2001-05-29 US US09/867,947 patent/US20030147907A1/en not_active Abandoned
-
2005
- 2005-06-15 US US11/154,421 patent/US20060024274A1/en not_active Abandoned
-
2011
- 2011-12-12 CY CY20111101230T patent/CY1112196T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2315269A1 (en) | 1999-07-01 |
| EP1042493A1 (en) | 2000-10-11 |
| JP2002516065A (ja) | 2002-06-04 |
| CN1322137C (zh) | 2007-06-20 |
| EP1895010B1 (en) | 2011-10-12 |
| ATE528405T1 (de) | 2011-10-15 |
| US6312683B1 (en) | 2001-11-06 |
| ES2373406T3 (es) | 2012-02-03 |
| AU1773299A (en) | 1999-07-12 |
| EP1895010A2 (en) | 2008-03-05 |
| US20030147907A1 (en) | 2003-08-07 |
| WO1999032646A1 (en) | 1999-07-01 |
| AU760287B2 (en) | 2003-05-08 |
| CN1285000A (zh) | 2001-02-21 |
| EP1895010A3 (en) | 2008-04-16 |
| JP4578678B2 (ja) | 2010-11-10 |
| PT1895010E (pt) | 2012-01-25 |
| US20060024274A1 (en) | 2006-02-02 |
| CY1112196T1 (el) | 2015-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1895010T3 (da) | Vektorer baseret på virus for infektiøs hesteanæmi (eiav) | |
| ATE358732T1 (de) | Anti-virale vektoren | |
| HUP0000442A2 (hu) | Lentivirális vektorok | |
| CY1112985T1 (el) | Χρηση αλληλουχιων dνα τριπλου ελικα για τη μεταφορα νουκλεοτιδικων αλληλουχιων | |
| DK0827545T3 (da) | Retrovirale vektorer | |
| EP1394259A3 (en) | Recombinant infectious non-segmented negative strand RNA virus | |
| CY1115010T1 (el) | ΕΝΑΣ ΜΟΛΥΣΜΑΤΙΚΟΣ cDNA ΚΛΩΝΟΣ ΤΟΥ ΙΟΥ ΤΟΥ ΧΟΙΡΕΙΟΥ ΑΝΑΠΑΡΑΓΩΓΙΚΟΥ ΚΑΙ ΑΝΑΠΝΕΥΣΤΙΚΟΥ ΣΥΝΔΡΟΜΟΥ ΒΟΡΕΙΟΥ ΑΜΕΡΙΚΗΣ (PRRS) ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΟΥ | |
| DE3581690D1 (de) | Klonierte dns-sequenzen, hybridisierbar mit genom-rns vom "lymphadenopathy-associated virus (lav)". | |
| ES2094744T3 (es) | Manipulaciones geneticas con el adn recombinante que contiene secuencias derivadas de los virus arn. | |
| DK0854197T3 (da) | Primere til påvisning af HIV-1 | |
| ATE205253T1 (de) | Induzierbare virusresistenz bei pflanzen | |
| DK0548234T3 (da) | Kloning af kyllingeanæmivirus DNA | |
| DK0599868T3 (da) | Polyphenoloxidase-gener | |
| DE69121975D1 (de) | Spezifischer Nachweis von Mycobacterium Tuberculosis | |
| EP0769553A4 (en) | DNA FRAGMENT, RECOMBINANT VECTOR THAT CONTAINS IT AND METHOD FOR EXPRESSING FOREIGN GENES WITH ITS USE | |
| DE69625356D1 (de) | cDNA KLON FÜR DEN SÜDAFRIKANISCHEN ARBOVIRUS NO.86 | |
| BR8506990A (pt) | Vetores de clonagem ou de expressao comportando o genoma do virus de eritroblastose aviaria e celulas transfectadas por estes vetores | |
| ZA941326B (en) | Polyribozyme capable of conferring viral resistance to plants, and resistant plants producing said ribozyme. | |
| DK631387D0 (da) | Virusvektor | |
| DE69232351D1 (de) | Ribozymstruktur die von den genomischen rns des hepatitis delta virus abgeleitet ist | |
| ES2133275T3 (es) | N-carbamoil-sarcosina-amidohidrolasa clonada. |